|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minemura H, Takagi K, Miki Y, Shibahara Y,
Nakagawa S, Ebata A, Watanabe M, Ishida T, Sasano H and Suzuki T:
Abnormal expression of miR-1 in breast carcinoma as a potent
prognostic factor. Cancer Sci. 106:1642–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gerratana L, Fanotto V, Bonotto M,
Bolzonello S, Minisini AM, Fasola G and Puglisi F: Pattern of
metastasis and outcome in patients with breast cancer. Clin Exp
Metastasis. 32:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higgins MJ and Baselga J: Targeted
therapies for breast cancer. J Clin Invest. 121:3797–3803. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piao HL and Ma L: Non-coding RNAs as
regulators of mammary development and breast cancer. J Mammary
Gland Biol Neoplasia. 17:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tavazoie SF, Alarcon C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massague J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: Dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hudson RS, Yi M, Esposito D, Watkins SK,
Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB,
et al: MicroRNA-1 is a candidate tumor suppressor and prognostic
marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu C, Zhang S, Wang Q and Zhang X: Tumor
suppressor miR-1 inhibits tumor growth and metastasis by
simultaneously targeting multiple genes. Oncotarget. 8:42043–42060.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu T, Hu K, Zhao Z, Chen G, Ou X, Zhang
H, Zhang X, Wei X, Wang D, Cui M and Liu C: MicroRNA down-regulates
proliferation and migration of breast cancer stem cells by
inhibiting the Wnt/β-catenin pathway. Oncotarget. 6:41638–41649.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu J, Zhao FP, Peng ZL, Zhang MM, Lin SX,
Liang BJ, Zhang B, Liu X, Wang L, Li G, et al: EZH2 promotes
angiogenesis through inhibition of miR-1/Endothelin-1 axis in
nasopharyngeal carcinoma. Oncotarget. 5:11319–11332. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheng JY, Shi BL and Chen HF:
Establishment and appraisal of DDP resistant variant of triple
negative breast cancer cell line MDA-MB-231. Cancer Res Prev Treat.
43:175–180. 2016.
|
|
17
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Datta J, Kutay H, Nasser MW, Nuovo GJ,
Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, et
al: Methylation mediated silencing of MicroRNA-1 gene and its role
in hepatocellular carcinogenesis. Cancer Res. 68:5049–5058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang YS, Chen WY, Yin JJ,
Sheppard-Tillman H, Huang J and Liu YN: EGF receptor promotes
prostate cancer bone metastasis by downregulating miR-1 and
activating TWIST1. Cancer Res. 75:3077–3086. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan D, Dong Xda E, Chen X, Wang L, Lu C,
Wang J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Y, Zheng J, Sun Y, Wu Z, Liu Z and
Huang G: MicroRNA-1 regulates cardiomyocyte apoptosis by targeting
Bcl-2. Int Heart J. 50:377–387. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis JM, Navolanic PM,
Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M,
Blagosklonny MV and McCubrey JA: Raf-1 and Bcl-2 induce distinct
and common pathways that contribute to breast cancer drug
resistance. Clin Cancer Res. 9:1161–1170. 2003.PubMed/NCBI
|
|
27
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi
Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the
resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J
Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duan Z, Lamendola DE, Duan Y, Yusuf RZ and
Seiden MV: Description of paclitaxel resistance-associated genes in
ovarian and breast cancer cell lines. Cancer Chemother Pharmacol.
55:277–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y,
Wang Y, Zhang J, Wu Z and Lu J: Weekly paclitaxel and cisplatin as
neoadjuvant chemotherapy with locally advanced breast cancer: A
prospective, single arm, phase II study. Oncotarget. 8:79305–79314.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hua L, Zhu G and Wei J: MicroRNA-1
overexpression increases chemosensitivity of non-small cell lung
cancer cells by inhibiting autophagy related 3-mediated autophagy.
Cell Biol Int. 42:1240–1249. 2018. View Article : Google Scholar : PubMed/NCBI
|
